RSS

Savara Pharmaceuticals

US group Savara Pharmaceuticals has secured $10 million in financial backing to develop AeroVanc, the trade name of the first inhaled antibiotic designed to address the growing number of MRSA lung infections in cystic fibrosis patients. more